55 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Days With Weight-monitoring on Sensor Logs at 6 WeeksPrimary· 6 weeks
This outcome will be measured by collecting number of days with weight-monitoring data. This measure will be collected from sensor logs within the apps for both intervention group (IG) and control group (CG).
Group
Value
95% CI
Intervention Group
35.8
± 6.0
Control Group
32.9
± 10.5
Number of Days With Weight-monitoring on Sensor Logs at 12 WeeksPrimary· 12 weeks
This outcome will be measured by collecting number of days with weight-monitoring data. This measure will be collected from sensor logs within the apps for both intervention group (IG) and control group (CG).
Group
Value
95% CI
Intervention Group
69.7
± 16.1
Control Group
60.1
± 18.7
Number of Days With Physical Activity on Sensor Logs at 6 WeeksSecondary· 6 weeks
This outcome measure will be measured by collecting number of days with physical activity data. These measures will be collected from sensor logs within the apps for both IG and CG.
Group
Value
95% CI
Intervention Group
36.7
± 10.9
Control Group
39.2
± 6.6
Number of Days With Physical Activity on Sensor Logs at 12 WeeksSecondary· 12 weeks
This outcome measure will be measured by collecting number of days with physical activity data. These measures will be collected from sensor logs within the apps for both IG and CG.
Group
Value
95% CI
Intervention Group
76.6
± 11.02
Control Group
69.6
± 17.3
Mean of Daily Steps on Physical Activity Sensor Logs at 6 WeeksSecondary· 6 weeks
This outcome measure will be measured by calculating the average daily steps at end of 6 weeks. These measures will be collected from sensor logs within the apps for both IG and CG.
Group
Value
95% CI
Intervention Group
2742
± 2499
Control Group
2638
± 1573
Mean of Daily Steps on Physical Activity Sensor Logs at 12 WeeksSecondary· 12 weeks
This outcome measure will be measured by calculating the average daily steps at end of 12 weeks. These measures will be collected from sensor logs within the apps for both IG and CG.
Group
Value
95% CI
Intervention Group
2887
± 2821
Control Group
2541
± 1604
Change From Baseline in Heart Failure Self-management Behaviors as Measured by the European Heart Failure Self-care Behavior Scale at 6 WeeksSecondary· Baseline, 6 weeks
The instrument used will be 9-item European Heart Failure Self-care Behavior Scale (HSBS; standardized score from 0 to 100 (every item is given an equal weight) with a higher score meaning better self-care). Items are on a Likert scale of 1 - 5. For calculating the standardized score, each item is reverse coded and then computed using the formula: (Sum of all ever-coded items - 9)\*2.7777
Group
Value
95% CI
Intervention Group
4.9
± 20.4
Control Group
-2.7
± 9.9
Change From Baseline in Heart Failure Self-management Behaviors as Measured by the European Heart Failure Self-care Behavior Scale at 12 WeeksSecondary· Baseline, 12 weeks
The instrument used will be 9-item European Heart Failure Self-care Behavior Scale (HSBS; standardized score from 0 to 100 (every item is given an equal weight) with a higher score meaning better self-care. Items are on a Likert scale of 1 - 5. For calculating the standardized score, each item is reverse coded and then computed using the formula: (Sum of all ever-coded items - 9)\*2.7777
Group
Value
95% CI
Intervention Group
9.3
± 16.5
Control Group
2.6
± 12.4
Change From Baseline in Heart Failure Self-management Behaviors as Measured by the European Heart Failure Self-care Behavior Scale at 24 WeeksSecondary· Baseline, 24 weeks
The instrument used will be 9-item European Heart Failure Self-care Behavior Scale (HSBS; standardized score from 0 to 100 (every item is given an equal weight) with a higher score meaning better self-care). Items are on a Likert scale of 1 - 5. For calculating the standardized score, each item is reverse coded and then computed using the formula: (Sum of all ever-coded items - 9)\*2.7777
Group
Value
95% CI
Intervention Group
10.2
± 13.4
Control Group
0.5
± 9.8
Change From Baseline in Heart Failure-related Quality of Life (QOL) on Kansas City Cardiomyopathy Questionnaire (KCCQ) at 6 WeeksSecondary· Baseline, 6 weeks
The instrument used will be items 13 - 15 on the KCCQ. Values for the QoL domain range from 0 to 100 with higher scores indicating better quality of life. Domain score will be transformed to a 0 to 100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100.
Group
Value
95% CI
Intervention Group
5.8
± 13.1
Control Group
8.7
± 15.3
Change From Baseline in Heart Failure-related Quality of Life (QOL) on Kansas City Cardiomyopathy Questionnaire (KCCQ) at 12 WeeksSecondary· Baseline, 12 weeks
The instrument used will be items 13 - 15 on the KCCQ. Values for the QoL domain range from 0 to 100 with higher scores indicating better quality of life. Domain score will be transformed to a 0 to 100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100.
Group
Value
95% CI
Intervention Group
8.2
± 13.5
Control Group
13.0
± 19.3
Change From Baseline in Heart Failure-related Quality of Life (QOL) on Kansas City Cardiomyopathy Questionnaire (KCCQ) at 24 WeeksSecondary· Baseline, 24 weeks
The instrument used will be items 13 - 15 on the KCCQ. Values for the QoL domain range from 0 to 100 with higher scores indicating better quality of life. Domain score will be transformed to a 0 to 100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100.
Group
Value
95% CI
Intervention Group
10.8
± 16.9
Control Group
15.4
± 19.6
Sponsor's own description
This study evaluates a sensor-controlled digital game (SCDG) to motivate self-management behaviors of weight monitoring and physical activity in older adults with heart failure (HF). Half of the participants will receive the SCDG app and weight monitoring and physical activity sensors and the other half will receive only the weight monitoring and physical activity sensors.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07531966 — Vascular Complications After Kidney Transplantation
· recruiting
Other University of Texas at Austin trials
Trials by the same sponsor.
NCT07319234 — Development of MENU Protocol
· NA
· not yet recruiting
NCT07480109 — Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity)
· NA
· not yet recruiting
NCT07069413 — Sibwatch: Optimizing Intervention Options for Infants and Toddler Siblings of Autistic Children
· NA
· not yet recruiting
NCT07370311 — A Culturally Adapted Decision Aid Intervention to Support Chinese American Dementia Caregivers in Feeding-Related Decisi
· NA
· not yet recruiting
NCT07441122 — Enhancing Attention in Elderly Using a Brain-Computer-Interface
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas at Austin
Last refreshed: 28 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03947983.